GILD  Gilead Sciences Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

+0.63 (+0.84%)

Growth Price

Undervalued by 115.68%

Stability Price

Overvalued by 32.44%

Company Metrics

  • P/E 6.67
  • P/S 3.07
  • P/B 6.46
  • EPS 11.39
  • Cash ROIC 49.59%
  • Cash Ratio 1.48
  • Dividend 1.88 / 2.53 %
  • Avg. Vol. 9.84M
  • Shares 1.52B
  • Market Cap. 100.31B

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


3 Key Questions for Gilead Sciences, Inc. in Q3
Motley Fool - Oct 26, 2016
Keith Speights owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has the following options: short October 2016 $85 calls on Gilead Sciences. Try any of our Foolish newsletter services free ...
Should You Buy Gilead Stock Going Into The Q3 Earnings? : Gilead Sciences, Inc ... - Amigobulls
Gilead Sciences Inc. (GILD) Short Interest Update - The Cerbat Gem
Better Buy: Biogen Inc. vs. Gilead Sciences, Inc.
Motley Fool - Oct 18, 2016
If you'd taken the same approach with Gilead Sciences (NASDAQ:GILD), your original investment would have more than tripled.
William Blair Positive on Gilead Sciences, Inc. (GILD) Following Data Releases
Smarter Analyst - Oct 25, 2016
Last Thursday, Gilead Sciences, Inc. (NASDAQ:GILD) announced Phase III POLARIS topline data with sofosbuvir (nucleotide polymerase inhibitor)/velpatasvir (NS5A inhibitor)/voxilaprevir (protease inhibitor) in treatment-na├»ve and treatment-experienced ...
Gilead Sciences: Stop Worrying About Hepatitis C. This is What You Should Be ... - Barron's (blog)
Gilead Sciences, Inc.: Why GILD Stock Could Surge 86% - Profit Confidential
Will Gilead Sciences Inc. Set Its Sights on Incyte?
Motley Fool - Oct 10, 2016
Evercore ISI investment bank recently conducted a survey of 244 biotech industry observers. The survey participants were asked which biotech is most likely to be acquired over the next 12 months.
Time To Put On The Watch List? - Gilead Sciences Inc. (NASDAQ:GILD), Corbus ...
The Voice Registrar - Oct 26, 2016
Gilead Sciences Inc. (NASDAQ:GILD) rose to $74.41 per share in the last trading day compared to a prior close of $74.15. The management team hold 0.4 percent of the stock.
Gilead Sciences, Inc.: GILD Stock Bears will Rejoice with This
Profit Confidential - Oct 12, 2016
Technical analysis is the method of discerning stock price trends and forecasting future price moves based on historical price data.
Gilead Stock: Could The FDA Warning Hurt Gilead Sciences Inc (GILD)? - Amigobulls
Gilead Sciences, Inc.: Why GILD Stock is a Good Income Opportunity - Income Investors
Stock Returns: Gilead Sciences Inc (NASDAQ:GILD) versus Vertex Pharmaceuticals ...
CML News - Oct 25, 2016
This is a snapshot to compare the stock returns for Gilead Sciences Inc (NASDAQ:GILD) versus Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) .
Company Update (NASDAQ:GILD): Gilead Sciences, Inc. Presents Results from ...
Smarter Analyst - Oct 24, 2016
Gilead Sciences, Inc. (NASDAQ:GILD) announced two-year (96-week) data from a Phase 3 study and 48-week data from two Phase 3b studies evaluating the safety and efficacy of switching virologically suppressed HIV-1 infected patients from regimens ...
Analyst Update: Clovis Oncology Inc, Calithera Biosciences Inc, and Gilead ...
Schaeffers Research (blog) - Oct 25, 2016
Gilead Sciences, Inc. stock is up 0.4% to $74.43 today, but still sits on a 31.5% year-over-year loss, after tapping a two-year low of $72.21 less than two weeks ago.
Company Update (NASDAQ:GILD): Gilead Sciences, Inc. Announces Clinical Updates
Smarter Analyst - Oct 20, 2016
Gilead Sciences, Inc. (NASDAQ:GILD) announced topline results from four international Phase 3 clinical studies (POLARIS-1, POLARIS-2, POLARIS-3 and POLARIS-4) evaluating an investigational, once-daily, fixed-dose combination of sofosbuvir (SOF), ...